A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Abroad (travel likely)RecruitingPHASE2

Conditions

Schizophrenia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Clinical Site, Lemon Grove, California, United States
Clinical Site, Miami Lakes, Florida, United States
Clinical Site, Chicago, Illinois, United States
Clinical Site, Staten Island, New York, United States
Clinical Site, DeSoto, Texas, United States

Study leads

MapLight Therapeutics
Study Director
MapLight Therapeutics

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

SCHIZOPHRENIA 1 (Disorder) · Schizoaffecitve Disorder

Abroad (travel likely)RecruitingPHASE1, PHASE2

New York, United States

Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

Schizophrenia · Cannabis Use Disorder

Abroad (travel likely)RecruitingPHASE1

West Haven, United States

SPARK Healthy Sleep

Schizophrenia and Related Disorders · Sleep Disturbance

Abroad (travel likely)Recruiting

Indianapolis, United States

Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.

Schizophrenia

Abroad (travel likely)Recruiting

Bron, France